RAIDEN RESOURCES LIMITED — Capital/Financing Update 2005

Dec 19, 2005

Rule 2.7, 3.10.3, 3.10.4, 3.10.5

Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 1/7/96. Origin: Appendix 5. Amended 1/7/98, 1/9/99, 1/7/2000, 30/9/2001, 11/3/2002.

Name of entity

Medical Monitors Limited

ABN 68 009 161 522

We (the entity) give ASX the following information.

Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

$\mathbf{1}$ ⁺Class of ⁺securities issued or to be Ĭ. Ordinary Shares issued 2. Options (Unlisted, expiring 30^th June 2005) Number of ⁺securities issued or to $\overline{2}$ 1,300,000 Ordinary Shares Ĭ. be issued (if known) or maximum number which may be issued $2.$ 15,000,000 Options (unlisted) Principal terms of the ⁺securities (eg, $\overline{3}$ if options, exercise price and expiry 1. Fully paid date; if partly paid *securities, the amount outstanding and due dates 2. Each Option to acquire one payment; if ⁺convertible for fully paid share by payment of securities, the conversion price and 4 cents at anytime up to $30^th$ dates for conversion) June 2007.

⁺ See chapter 19 for defined terms.

4	Do the + securities rank equally in all respects from the date of allotment with an existing + class of quoted * securities? If the additional securities do not rank equally, please state: the date from which they do the extent to which they participate for the next dividend, of the case (in $\mathbf{a}$ trust. distribution) or interest payment the extent to which they do not rank equally, other than in relation to the next dividend,	Yes, the Ordinary Shares rank equally 1. 2. Yes, but the Options (exercisable at \$0.04 each expiring 30/06/07) will not be quoted
	distribution or interest payment
5.	Issue price or consideration	\$0.04 each Ordinary Share 1.
		Nil consideration each Option 2.
6	Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)	This issue of shares and (unlisted) options was approved by shareholders at the Annual General Meeting, held 30 th November 2004, and as documented in the Notice of General Meeting, dated 28 th October 2004.
7	Dates of entering + securities into uncertificated holdings or despatch of certificates	23 December 2005
		Number + Class
8	Number + class and of all ASX *securities quoted on (including the securities in clause 2 if applicable)	301,793,524 Ordinary Shares

⁺ See chapter 19 for defined terms.

	Number
all Number and + class of *securities not quoted on $\text{ASK}$ 15,000,000 $(including the securities in clause 2)$ if applicable)

$10^°$ trust, distribution policy) on the increased capital (interests)

Number	+ Class
15,000,000	Options (exercisable at \$0.04 each expiring 30/06/07)

Dividend policy (in the case of a $\boxed{\text{No}}$ dividend policy has been formulated by the company at this stage. It is the Board's intention to defer the development of a dividend policy until surplus cash flows are available.

Part 2 - Bonus issue or pro rata issue

$\mathbf{1}$	security holder approval Ĭs. required?
12	Is the issue renounceable or non- renounceable?
13	Ratio in which the $\tau$ securities will be offered
14	+ Class of + securities to which the offer relates
15	determine *Record date $\mathfrak{t}_0$ entitlements
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?
17	Policy for deciding entitlements in relation to fractions
18	Names of countries in which the entity has *security holders who will not be sent issue new documents
	Note: Security holders must be told how their entitlements are to be dealt with.
	Cross reference: rale 7.7.
19	Closing date for of receipt acceptances or renunciations

⁺ See chapter 19 for defined terms.

Appendix3B Newissueannouncement

20	Names of any underwriters
21	Amount of any underwriting fee or commission
22	Names of any brokers to the issue
23	Fee or commission payable to the broker to the issue
24	Amount of any handling fee payable to brokers who lodge acceptances renunciations on behalf of ΘГ *securityholders
25	If the issue is contingent on *security holders' approval, the date of the meeting
26	Date entitlement and acceptance form and prospectus or Product Disclosure Statement will be sent to persons entitled
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders
28	Date rights trading will begin (if applicable)
29	Date rights trading will end (if applicable)
30	How do + security holders sell their entitlements through a in full broker?
31	How do + security holders sell part of their entitlements through a broker and accept for the balance?

⁺ See chapter 19 for defined terms.

32 How do +security holders dispose of their entitlements (except by sale through a broker)?

33 +Despatchdate

Part 3 - Quotation of securities

You need only complete this section if you are applying for quotation of securities

• 34 Type of securities (tick one)
• $(a)$ Securities described in Part 1 ⊠
• $(b)$ All other securities

Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentivesharesecurities whenrestriction ends, securities issued on expiry or conversion of convertible securities

Entities that have ticked box 34(a)

Additional securities forming a new class of securities

(If the additional securities do not form a new class, go to $43$ )

Tick to indicate you are providing the information or documents

• If the *securities are *equity securities, the names of the 20 largest holders of the additional +securities, and the number and percentage of additional +securities held by thoseholders
• 36 If the "securities are "equity securities, a distribution schedule of the additional *securities setting out the number of holders in the categories $1 - 1,000$ $1,001 - 5,000$ $5,001 - 10,000$ $10.001 - 100.000$ 100,001 and over

37

$35$

A copy of any trust deed for the additional +securities

(now go to $43$ )

⁺ See chapter 19 for defined terms.

Entities that have ticked box 34(b)

• 38 Number of securities for which ⁺quotation is sought
• 39 Class of ⁺securities for which quotation is sought
• 40 Do the +securities rank equally in all respects from the date of allotment with an existing ⁺class of quoted *securities?

If the additional securities do not rank equally, please state:

• $\bullet$ the date from which they do
• the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment
• the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment
• 41 Reason for request for quotation now

Example: in the case of restricted securities, end of restrictionperiod

(if issued upon conversion of another security, clearly identify that other security)

$42$ Number and ⁺class of all ⁺securities quoted on ASX (including the securities in clause 38)

Number	+ Class

(now go to $43$ )

		+ See chapter 19 for defined terms.
--	--	-------------------------------------	--	--	--	--

All entities

Fees

43

	Payment method (tick one)
	Invoice
	Electronic payment made Note: Payment may be made electronically if Appendix 3B is given to ASX electronically at the same time.
	Periodic payment as agreed with the home branch has been arranged Note: Arrangements can be made for employee incentive schemes that involve frequent issues of securities

Quotationagreement

• *Quotation of our additional*securities is in ASX's absolute discretion. ASX may $\mathbf{1}$ quote the +securities on any conditions it decides.
• $\overline{\mathcal{L}}$ We warrant the following to ASX.
• The issue of the "securities to be quoted complies with the law and is not for an illegal purpose.
• There is no reason why those *securities should not be granted *quotation.
• An offer of the "securities for sale within 12 months after their issue will not require disclosure under section $707(3)$ or section $1012C(6)$ of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

• Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any *securities to be quoted and that no-one has any right to return any *securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the *securities be quoted.
• We warrant that if confirmation is required under section 1017F of the Corporations Act in relation to the 'securities to be quoted, it has been provided at the time that we request that the "securities be quoted.
• If we are a trust, we warrant that no person has the right to return the *securities to be quoted under section 1019B of the Corporations Act at the time that we request that the *securities be quoted.

⁺ See chapter 19 for defined terms.

• $\overline{3}$ We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
• $\overline{4}$ We give ASX the information and documents required by this form. If any information or document not available now, will give it to ASX before tquotation of the *securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are true and complete.

Sign here:

Date: 20/121/05

Director

Print name:

Dr Allan Shell

$\div$ See chapter 19 for defined terms.